Cipla Limited (NSE:CIPLA)
1,442.20
-40.70 (-2.74%)
Mar 28, 2025, 3:29 PM IST
Cipla Revenue
Cipla had revenue of 69.62B INR in the quarter ending December 31, 2024, with 7.01% growth. This brings the company's revenue in the last twelve months to 267.20B, up 6.39% year-over-year. In the fiscal year ending March 31, 2024, Cipla had annual revenue of 255.37B with 13.20% growth.
Revenue (ttm)
267.20B
Revenue Growth
+6.39%
P/S Ratio
4.36
Revenue / Employee
9.62M
Employees
27,764
Market Cap
1,164.75B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 255.37B | 29.77B | 13.20% |
Mar 31, 2023 | 225.59B | 8.51B | 3.92% |
Mar 31, 2022 | 217.08B | 25.87B | 13.53% |
Mar 31, 2021 | 191.21B | 20.40B | 11.94% |
Mar 31, 2020 | 170.81B | 7.57B | 4.64% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 516.03B |
Divi's Laboratories | 90.78B |
Mankind Pharma | 116.41B |
Apollo Hospitals Enterprise | 211.46B |
Zydus Lifesciences | 222.47B |
Aurobindo Pharma | 309.22B |
Alkem Laboratories | 127.57B |
Fortis Healthcare | 75.61B |
Cipla News
- 13 hours ago - Nifty 50 top losers this week: Zomato, IndusInd Bank, Cipla, Mahindra & Mahindra and more - Business Upturn
- 1 day ago - Nifty 50 top losers today, March 28: Wipro, IndusInd Bank, Shriram Finance, Cipla and more - Business Upturn
- 3 days ago - Nifty 50 top losers today, March 26: NTPC, Tech Mahindra, Cipla, Bajaj Finance and more - Business Upturn
- 10 days ago - Cipla signs pact with Taiwan drug firm - The Times of India
- 11 days ago - Cipla and Formosa Pharmaceuticals sign multi-regional licensing deal for clobetasol suspension - Business Upturn
- 16 days ago - Nifty 50 top gainers today, March 13: Bharat Electronics, State Bank of India, ONGC, Cipla and more - Business Upturn
- 4 weeks ago - Macquarie bullish on select pharma and CDMO stocks, bearish on hospitals - Business Upturn
- 5 weeks ago - Top stocks to watch today on February 21: Cipla, NTPC Green Energy, RVNL, Delta Corp, HG Infra and more - Business Upturn